Xencor, Inc. (XNCR)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Xencor, Inc. (XNCR) trades at $12.43 with AI Score 56/100 (Grade B). Xencor, Inc. is a clinical-stage biopharmaceutical company focused on developing engineered monoclonal antibody and cytokine therapeutics. Market cap: $921.58M, Sector: Healthcare.
Last analyzed: May 6, 2026Analyst Coverage for XNCR: XNCR does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates XNCR against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
XNCR: 2/4 perspectives are bearish. Dominant signal: Seth Klarman bearish.
Xencor, Inc. (XNCR) Healthcare & Pipeline Overview
Xencor, Inc. is a clinical-stage biopharmaceutical company specializing in engineered monoclonal antibodies and cytokine therapeutics for cancer and autoimmune diseases. Their XmAb platform differentiates them in a competitive market, with multiple clinical trials underway and strategic partnerships driving growth. The company operates within the rapidly evolving biotechnology sector.
What Is the Investment Thesis for XNCR?
Xencor's investment thesis hinges on its proprietary XmAb technology platform and its ability to generate a diverse pipeline of novel antibody and cytokine therapeutics. The company's clinical-stage programs, particularly Plamotamab and Vudalimab, represent significant potential value drivers. Successful clinical trial outcomes and subsequent regulatory approvals could lead to substantial revenue growth. Xencor's gross margin of 94.4% indicates strong profitability potential for approved products. However, the company's negative profit margin of -185.7% reflects significant ongoing R&D expenses. Key risks include clinical trial failures, regulatory hurdles, and competition from other biotechnology companies. The company's beta of 0.99 suggests market-average volatility. Upcoming clinical trial readouts for key pipeline assets will be critical catalysts.
Based on FMP financials and quantitative analysis
XNCR Key Highlights
- Market capitalization of $0.92 billion reflects investor valuation of Xencor's pipeline and technology.
- Gross margin of 94.4% demonstrates strong potential profitability of approved products.
- Negative profit margin of -185.7% indicates significant investment in research and development.
- Beta of 0.99 suggests market-average volatility compared to the broader market.
- Extensive pipeline with multiple programs in Phase 1 and Phase 2 clinical trials indicates potential for future growth.
Who Are XNCR's Competitors?
XNCR is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| TNGX Tango Therapeutics, Inc. | $30.55 | +2.44% | 4B | 64 |
| ANAB AnaptysBio, Inc. | $54.24 | +4.11% | $2.34B | 79 |
| SNDX Syndax Pharmaceuticals, Inc. | $18.02 | +0.61% | $1.60B | 79 |
| CGEN Compugen Ltd. | $2.02 | -0.98% | $191.00M | 76 |
| ABCL AbCellera Biologics Inc. | $5.23 | -0.76% | $1.60B | 76 |
| XFOR X4 Pharmaceuticals, Inc. | $3.97 | +2.32% | $374.45M | 76 |
| GLUE Monte Rosa Therapeutics, Inc. | $18.14 | +6.11% | $1.18B | 68 |
| TLX Telix Pharmaceuticals Limited | $9.46 | +0.13% | $3.21B | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are XNCR's Key Strengths?
- Proprietary XmAb technology platform.
- Diverse pipeline of clinical-stage programs.
- Strong partnerships with pharmaceutical companies.
- High gross margin potential.
What Are XNCR's Weaknesses?
- Negative profit margin due to high R&D expenses.
- Reliance on clinical trial success.
- Competition from larger pharmaceutical companies.
- Dependence on key partnerships.
What Could Drive XNCR Stock Higher?
- Phase II clinical trial results for Vudalimab in metastatic castration-resistant prostate cancer (2027).
- Phase I clinical trial results for XmAb306 in solid tumors (2027).
- Continued development of Plamotamab in Phase I clinical trial for non-Hodgkin lymphoma.
- Advancement of Tidutamab in Phase II clinical trial for neuroendocrine tumors.
- Potential new partnerships or licensing agreements for XmAb platform technologies.
What Are the Key Risks for XNCR?
- Clinical trial failures for key pipeline assets.
- Regulatory delays or rejection of marketing applications.
- Competition from other biotechnology companies developing similar therapies.
- Dependence on key partnerships for revenue generation.
- High R&D expenses impacting profitability.
What Are the Growth Opportunities for XNCR?
- Expansion of Plamotamab Development: Plamotamab, a tumor-targeted antibody in Phase I clinical trial for non-Hodgkin lymphoma, represents a significant growth opportunity. The market for non-Hodgkin lymphoma therapeutics is projected to reach $12.8 billion by 2028. Positive clinical trial results and subsequent regulatory approval could drive substantial revenue growth for Xencor. The company's XmAb platform allows for the optimization of Plamotamab's efficacy and safety profile, providing a competitive advantage.
- Advancement of Vudalimab Program: Vudalimab, a bispecific antibody in Phase II clinical trial for metastatic castration-resistant prostate cancer and other solid tumors, offers another key growth driver. The prostate cancer therapeutics market is expected to reach $12 billion by 2027. Successful clinical development and commercialization of Vudalimab could significantly increase Xencor's market share. The bispecific antibody format enhances Vudalimab's ability to target and eliminate tumor cells.
- Development of Tidutamab for Neuroendocrine Tumors: Tidutamab, currently in Phase II clinical trial for neuroendocrine tumors, presents a targeted growth opportunity. The neuroendocrine tumor therapeutics market is estimated at $1.8 billion. Positive trial outcomes could lead to regulatory approval and commercial success. Xencor's antibody engineering expertise contributes to Tidutamab's potential efficacy and safety.
- Partnerships and Licensing Agreements: Xencor's collaborations with pharmaceutical companies like Novartis and its license agreement with Caris Life Sciences provide opportunities for revenue generation and pipeline expansion. These partnerships allow Xencor to leverage external resources and expertise, accelerating the development and commercialization of its therapeutics. Strategic alliances can also provide non-dilutive funding for research and development activities.
- Expansion into New Therapeutic Areas: Xencor's XmAb platform can be applied to a wide range of therapeutic areas beyond cancer and autoimmune diseases. Exploring new indications, such as infectious diseases or neurological disorders, could unlock additional growth opportunities. The company's expertise in antibody engineering and cytokine therapeutics positions it well to address unmet medical needs in diverse disease areas. This strategic diversification could mitigate risks associated with reliance on specific therapeutic markets.
What Opportunities Does XNCR Have?
- Expansion into new therapeutic areas.
- Advancement of pipeline programs through clinical trials.
- Strategic acquisitions or licensing deals.
- Increased adoption of antibody therapeutics.
What Threats Does XNCR Face?
- Clinical trial failures.
- Regulatory hurdles.
- Patent expirations.
- Competition from biosimilars.
What Are XNCR's Competitive Advantages?
- Proprietary XmAb technology platform for antibody engineering.
- Extensive patent portfolio protecting its antibody technologies and therapeutic candidates.
- Expertise in cytokine engineering and bispecific antibody development.
- Established partnerships with major pharmaceutical companies.
What Does XNCR Do?
Xencor, Inc., founded in 1997 and headquartered in Monrovia, California, is a clinical-stage biopharmaceutical company dedicated to discovering and developing engineered monoclonal antibody and cytokine therapeutics. The company's core technology, the XmAb platform, allows for the creation of novel antibody and cytokine therapies with improved efficacy, safety, and manufacturability. Xencor's pipeline includes a range of programs targeting cancer and autoimmune diseases. Key products and programs include Sotrovimab (targeting SARS-CoV-2), Ultomiris (for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome), and Monjuvi (for relapsed or refractory diffuse large B-cell lymphoma). Additionally, Xencor is developing Plamotamab (Phase I, non-Hodgkin lymphoma), Vudalimab (Phase II, metastatic castration-resistant prostate cancer and other solid tumors), and Tidutamab (Phase II, neuroendocrine tumors). The company also has several other programs in Phase I clinical trials, including XmAb306, XmAb104, XmAb841, XmAb564, AMG 509, and XmAb819. Xencor collaborates with other pharmaceutical companies, including Novartis, and has a license agreement with Caris Life Sciences. Xencor's strategic focus on innovative antibody engineering positions it within the competitive biotechnology landscape.
What Products and Services Does XNCR Offer?
- Discovers and develops engineered monoclonal antibody therapeutics.
- Creates cytokine therapeutics for cancer and autoimmune diseases.
- Utilizes the XmAb platform to improve antibody efficacy, safety, and manufacturability.
- Conducts clinical trials to evaluate the safety and efficacy of its drug candidates.
- Seeks regulatory approval for its therapeutics from agencies like the FDA.
- Commercializes approved therapeutics through its own sales force or partnerships.
- Collaborates with other pharmaceutical companies to develop and market new therapies.
How Does XNCR Make Money?
- Develops and out-licenses antibody technologies.
- Generates revenue through milestone payments and royalties on partnered programs.
- Commercializes proprietary therapeutics directly.
- Focuses on high-value therapeutic areas with unmet medical needs.
What Industry Does XNCR Operate In?
Xencor operates within the biotechnology industry, a sector characterized by high growth potential and substantial risk. The market for antibody therapeutics is expanding, driven by advances in protein engineering and a growing understanding of disease mechanisms. Competition is intense, with numerous companies developing novel therapies for cancer and autoimmune diseases. Xencor's XmAb platform provides a competitive advantage by enabling the creation of differentiated antibody therapeutics. The biotechnology industry is subject to stringent regulatory oversight and faces challenges related to clinical trial success and market access.
Who Are XNCR's Key Customers?
- Patients with cancer and autoimmune diseases.
- Pharmaceutical companies seeking to license or partner on novel antibody therapeutics.
- Healthcare providers who prescribe Xencor's approved therapies.
- Research institutions collaborating on drug discovery and development.
XNCR Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Xencor's recent insider buying signals strong confidence from those closest to the company, suggesting they believe the stock is undervalued.
- The community sentiment around Xencor has been increasingly positive, with many highlighting the potential of their novel XmAb technology platform.
- Market perception seems to be shifting towards recognizing the long-term value of Xencor's pipeline, especially their bispecific antibodies.
- The company's strategic partnerships with larger pharmaceutical firms are viewed as a validation of their technology and a potential source of future revenue.
Bear Case
- Some worry that Xencor's reliance on strategic partnerships could make them vulnerable if those partnerships falter or change direction.
- The community has expressed concerns about potential competition in the bispecific antibody space, which could erode Xencor's market share.
- Recent market developments suggest investors are becoming more risk-averse, which could negatively impact biotech companies like Xencor that require significant R&D investment.
- There's a lingering perception that Xencor's pipeline is still early-stage, and the path to commercialization may be longer and more uncertain than some anticipate.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · January 2026
XNCR Latest News
-
Earnings Scheduled For May 6, 2026
benzinga · May 6, 2026
-
Corcept Therapeutics (CORT) Reports Q1 Loss, Misses Revenue Estimates
Yahoo! Finance: XNCR News · May 1, 2026
-
Stocks That Hit 52-Week Lows On Wednesday
benzinga · Oct 4, 2023
-
Stocks That Hit 52-Week Lows On Tuesday
benzinga · Oct 3, 2023
XNCR Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for XNCR.
Price Targets
Wall Street price target analysis for XNCR.
XNCR MoonshotScore
What does this score mean?
The MoonshotScore rates XNCR's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Latest News
Leadership: Bassil I. Dahiyat
CEO
Bassil I. Dahiyat is the Chief Executive Officer of Xencor, Inc. He co-founded the company in 1997. Dahiyat holds a Ph.D. in Chemical Engineering from the California Institute of Technology and a B.S.E. in Biomedical Engineering from the University of Pennsylvania. His expertise lies in protein engineering and drug development. Prior to Xencor, Dahiyat conducted research in protein design and computational biology. He has published numerous scientific articles and holds several patents in the field of antibody engineering.
Track Record: Under Dahiyat's leadership, Xencor has advanced multiple antibody therapeutics into clinical development and secured partnerships with major pharmaceutical companies. Key milestones include the development and commercialization of Monjuvi and the advancement of Plamotamab and Vudalimab into clinical trials. Dahiyat has overseen the expansion of Xencor's XmAb platform and the growth of its pipeline.
What Investors Ask About Xencor, Inc. (XNCR) — Healthcare
What does Xencor, Inc. do?
Xencor, Inc. is a clinical-stage biopharmaceutical company that focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics. The company's proprietary XmAb technology platform enables the creation of novel antibody therapies with improved efficacy, safety, and manufacturability. Xencor's pipeline includes programs targeting cancer and autoimmune diseases, with several candidates in clinical development. The company generates revenue through partnerships, licensing agreements, and the commercialization of its own proprietary therapeutics.
What do analysts say about XNCR stock?
Analyst coverage of XNCR stock reflects a focus on the company's pipeline potential and the XmAb technology platform. Valuation metrics typically consider the potential revenue from key pipeline assets, such as Plamotamab and Vudalimab, and the likelihood of clinical trial success and regulatory approval. Growth considerations include the expansion of the pipeline, strategic partnerships, and the potential for new therapeutic applications of the XmAb platform. Analyst ratings and price targets vary based on individual assessments of these factors. No buy or sell recommendations are made here.
What are the main risks for XNCR?
The main risks for XNCR include clinical trial failures, regulatory hurdles, and competition from other biotechnology companies. Clinical trial failures can significantly impact the company's valuation and future prospects. Regulatory delays or rejection of marketing applications can also negatively affect revenue projections. Competition from companies developing similar therapies poses a threat to market share. Additionally, Xencor faces risks related to patent expirations, dependence on key partnerships, and high R&D expenses.
What is Xencor, Inc.'s drug pipeline status?
Xencor, Inc.'s drug pipeline includes multiple programs in various stages of clinical development. Key therapeutic areas include cancer and autoimmune diseases. Plamotamab, a tumor-targeted antibody, is in Phase I clinical trial for non-Hodgkin lymphoma. Vudalimab, a bispecific antibody, is in Phase II clinical trial for metastatic castration-resistant prostate cancer and other solid tumors. Tidutamab is in Phase II clinical trial for neuroendocrine tumors. Upcoming catalysts include clinical trial readouts for these and other pipeline assets, which could drive significant stock price movement.
How does Xencor, Inc. manage patent expiration risks?
Xencor, Inc. manages patent expiration risks through a multi-faceted approach. The company actively seeks to extend patent protection for its key technologies and therapeutic candidates through the filing of new patent applications and the development of novel formulations. Xencor also focuses on building a robust intellectual property portfolio around its XmAb platform, which provides a competitive advantage. Furthermore, the company pursues strategic partnerships and licensing agreements to mitigate the impact of potential biosimilar competition and lifecycle management challenges.
What are the key factors to evaluate for XNCR?
Xencor, Inc. (XNCR) holds an AI score of 56/100 (moderate). Not financial advice.
How frequently does XNCR data refresh on this page?
XNCR prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven XNCR's recent stock price performance?
Xencor, Inc. (XNCR) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary XmAb technology platform. See the News tab for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on publicly available sources and may be subject to change.
- Clinical trial outcomes are inherently uncertain and may differ from expectations.